Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the
relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and
equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham
Pharmaceuticals) in a test population of 24 adult individuals under fed conditions.